Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000492863 | SCV000581501 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-11-20 | criteria provided, single submitter | clinical testing | The c.160delG pathogenic mutation, located in coding exon 2 of the BMPR1A gene, results from a deletion of one nucleotide at nucleotide position 160, causing a translational frameshift with a predicted alternate stop codon (p.D54Ifs*6). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV003762754 | SCV004427030 | pathogenic | Juvenile polyposis syndrome | 2022-12-31 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 429105). This variant has not been reported in the literature in individuals affected with BMPR1A-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asp54Ilefs*6) in the BMPR1A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BMPR1A are known to be pathogenic (PMID: 11536076, 12417513). |